2 terminated, 1 withdrawn. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow M9241: new trials by email Literature Review of M9241 trials Research Report on M9241
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer M7824, M9241, SBRT - Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2021-06-15 | 2022-05-18 |
| Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial Bintrafusp Alfa, Immunocytokine NHS-IL12, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2021-03-07 | 2023-12-27 | |
| A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12) Avelumab, M9241, Avelumab (Once weekly) - Advanced Solid Tumors | Phase 1 | Terminated | EMD Serono Research & Development Institute, Inc. | 52 | 2017-01-31 | 2024-09-20 |
Breast Neoplasms (1) · Pancreatic Neoplasms (1)
EMD Serono Research & Development Institute, Inc. (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (2) · Belgium (1) · France (1) · Hungary (1) · Italy (1) · Netherlands (1) · Spain (1)
Meghan Karuturi, MD (1) · Udo Rudloff, M.D. (1)
2017 (1)